Skip to main content

Advertisement

ADVERTISEMENT

News

Efficacy and Safety of EDX110 for Hard-To-Heal Wounds 

https://clinicaltrials.gov/study/NCT06640985

A Convatec-sponsored post-market CT of 80 patients will determine the efficacy and safety of EDX110 (NO) in DFUs and VLUs resulting from venous insufficiency or diabetes with primary outcome of percentage area reduction at 12 weeks. Not yet recruiting; estimated study completion is Nov 2025. clinicaltrials.gov

Advertisement

Advertisement

Advertisement